San Francisco, California, December 12, 2016 – Medizone International, Inc. (The Company) (OTCQB:MZEI) Following its recently announced EPA approval to enter the US market with its WHO Award winning and peer reviewed AsepticSure® Hospital Disinfection Technology, the Company today announces Mexico has agreed to grant a patent for its HEALTHCARE FACILITY DISINFECTING PROCESS AND SYSTEM WITH OXYGEN/OZONE MIXTURE. This patent essentially conformed with the claims to those previously granted for the European Union. Countries that have now granted coverage for this revolutionary hospital disinfection technology include Canada, the United States, Mexico, China, Singapore, The United Kingdom, France and Germany with additional applications pending and processing.
Additional patent grants for BIO-TERRORISM COUNTERACTION USING OZONE AND HYDROGEN PEROXIDE have been granted by the United States, The United Kingdom, France and Germany.
A patent covering SPORTS EQUIPMENT AND FACILITY DISINFECTION has been granted in the United States and a Notice of Allowance received for Canada.
Medizone’s Chairman of the Board and CEO Edwin Marshall commented, “developing and proving a room disinfection system that consistently achieves 100% kill of all vegetative and spore forming bacteria as well as viral pathogens throughout the entire space being disinfected utilizing a ‘green’ technology has proven to be a considerable journey. Management is excited about our US market entry and is pleased that International patent authorities continue to recognize the unique nature of this science and continue to grant the company patent protection for what is sure to be greatly expanding commercial opportunity as we move into 2017.”
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]
For more information, visit: